Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone reflects strong support and enthusiasm for the research, with posts citing specific studies, such as those showing restored ion channel activity and improved NK cell function, and mentioning potential clinical benefits. Phrases like 'restored activity,' 'potential benefit,' and references to multiple supporting studies demonstrate a positive outlook and a deep engagement with the scientific findings.
Most discussions support the article's findings, emphasizing the potential benefits of LDN in ME/CFS treatment and referencing the restoration of NK cell activity and TRPM3 ion channels.
The discussions reveal high interest, with multiple references to recent studies, clinical effects, and potential treatments, showing curiosity and engagement with the research.
While many posts acknowledge the study and mention specific mechanisms like TRPM3 channels, few provide in-depth analysis or personal insights, indicating moderate but meaningful engagement.
The discussions could influence clinical considerations and patient approaches to ME/CFS, reflecting a significant potential impact of the research on treatment options and understanding of the condition.
Professor Sonya Marshall-Gradisnik sheds new light on the pathological processes underlying myalgic encephalomyelitis/chronic fatigue syndrome (#ME/#CFS). These discoveries now paves the way for future #pharmacotherapeutic interventions. Watch now: https://t.co/CHKYiofZvi
Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wieder erfreuliche Effekte, auch wenn es natürlich das Grundproblem nicht lösen kann. https://t.co/YefjXsjA3o
Und auch diese Studie zeigt den potenziellen therapeutischen Nutzen von niedrig dosiertem Naltrexon bei Myalgischer Enzephalomyelitis/Chronischem Müdigkeitssyndrom auf: https://t.co/DmG94ivVJN #MECFS #LongCovid #COVID19
Potential therapeutic benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 ion channels in pathophysiology and treatment. #MEartikler https://t.co/E9fkuCioG2
"Potential Therapeutic Benefit of #LowDoseNaltrexone in #MyalgicEncephalomyelitis/#ChronicFatigueSyndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment" Free: https://t.co/2KRwXZ5lfp #MEcfs #CFS #MyalgicE
@ahandvanish Some of these come to mind: LDN doi: 10.3389/fimmu.2021.687806 Inosine Pranobex doi: 10.1002/eji.201847948 Interferon (alpha) doi: 10.3109/08820139609059298 certain probiotics doi: 10.1615/ForumImmunDisTher.2016017095 ampligen OM-85 BV https://t.co/6IdliQQXTq
Professor Sonya MarshallGradisnik discusses how impaired TRPM3 ion channel activity contributes to immune and neurological dysfunction in ME/CFS. Understanding these mechanisms may lead to targeted therapies for this…
Exploring the potential of low-dose Naltrexone to treat ME/CFS by modulating TRPM3 ion channels, which are involved in immune and neurological functions. Patients taking LDN showed restored TRPM3 activity, suggesting a…
Explores how low-dose Naltrexone may help treat ME/CFS by targeting the TRPM3 ion channel, which affects immune and neurological functions. Patients taking LDN showed restored TRPM3 activity in natural killer cells…
@Kelmyer5 Another link of study on LDN aimed at ME/CFS. https://t.co/NtXshCiSVw
#Naltrexona a bajas dosis, no es un milagro, pero algo hace. Hay que ir poco a poco...pero se nota. https://t.co/t5HhLnP5fw
2021 study by Griffith University found faulty ion channels in natural killer cells blocking calcium transport in ME/CFS & #LongCovid patients. Cells treated in vitro w/ naltrexone were restored. Now comes the RCT
https://t.co/FrOi3phWET
RT @RYsendyck: @ahandvanish Some of these come to mind: LDN doi: 10.3389/fimmu.2021.687806 Inosine Pranobex doi: 10.1002/eji.201847948 I…
RT @RYsendyck: @ahandvanish Some of these come to mind: LDN doi: 10.3389/fimmu.2021.687806 Inosine Pranobex doi: 10.1002/eji.201847948 I…
RT @RYsendyck: @ahandvanish Some of these come to mind: LDN doi: 10.3389/fimmu.2021.687806 Inosine Pranobex doi: 10.1002/eji.201847948 I…
@ahandvanish Some of these come to mind: LDN doi: 10.3389/fimmu.2021.687806 Inosine Pranobex doi: 10.1002/eji.201847948 Interferon (alpha) doi: 10.3109/08820139609059298 certain probiotics doi: 10.1615/ForumImmunDisTher.2016017095 ampligen OM-85 BV https://t.co/6IdliQQXTq
RT @meta201012: @MichelleSairsel @evandegr @agy_lena Here are some studies. However, there are numerous anecdotal reports of patients who h…
@MichelleSairsel @evandegr @agy_lena Here are some studies. However, there are numerous anecdotal reports of patients who had significant improvement in quality of life parameters including fatigue, sleep, and pain. https://t.co/nJxnDHWLbQ https://t.co/Ne7GCru1wx
@AndrewG76201347 https://t.co/LSVaXJHzOf
@curemecfs @sibylle_berlin This looks very complicated, but just so you know the name etc. https://t.co/61CquQKKDp
@AmandaHaddock A combination of H1 and H2 antagonists is used by #LongCovid patients. Low-dose naltrexone for ↑NK cell function. https://t.co/uUwfys6S3Q https://t.co/lv2jhPfErn https://t.co/1hPCPFSaNU "treated with cetirizine 10 mg b.i.d. and famotidine 20 mg b.i.d. plus standard-of-care"
RT @renesugar: @clarejdaly @angryhacademic LDN improves NK cell function in addition to other effects. Herpesviruses react to NK cells; th…
RT @renesugar: @clarejdaly @angryhacademic LDN improves NK cell function in addition to other effects. Herpesviruses react to NK cells; th…
RT @renesugar: @clarejdaly @angryhacademic LDN improves NK cell function in addition to other effects. Herpesviruses react to NK cells; th…
@clarejdaly @angryhacademic LDN improves NK cell function in addition to other effects. Herpesviruses react to NK cells; the resulting neuroinflammation affects sleep. https://t.co/p7PL1CIxOD https://t.co/lv2jhPfErn "ME/CFS patients taking LDN have restored TRPM3-like ionic currents in NK cells"
@medtomwillems @minismental77 Das sind 3 Paper zu Naltrexon bei ME: https://t.co/kge54n4G37 https://t.co/V6yNHTG8CW https://t.co/sh5h5oCnkI
Another medication that has helped me a lot is low dose naltrexone, which reduces adhesion of leukocytes and endothelial cells! This helps with inflammation in general but can't be a coincidence https://t.co/ah9mLsBRY6
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment https://t.co/nMsaJNHjkj
RT @RWittenbrink: Und auch diese Studie zeigt den potenziellen therapeutischen Nutzen von niedrig dosiertem Naltrexon bei Myalgischer Enzep…
@violinvet @Naomi_D_Harvey @CyruxiME You can import it into the US if you want it. Your doctor can read this if he or she wants to. Otherwise, make your own from the usual 50 mg. tablet. It's just mathematics. https://t.co/vhezRovHTn
@RenzPolster @TimHuttonAu @pausedME Very interesting to see this convergence wrt pregnenolone. This Australian team you cite has shifted for some reason towards LDN of late with respect to restoring TRPM3 activity. Not fully sure the pros & cons of each. https://t.co/BR1enqgtNB
@Naomi_D_Harvey Also a couple of papers on LDN for chronic pain and for ME/CFS, in case they are useful: https://t.co/gEeMZozmie https://t.co/I6Pkt1er3S
RT @RWittenbrink: Und auch diese Studie zeigt den potenziellen therapeutischen Nutzen von niedrig dosiertem Naltrexon bei Myalgischer Enzep…
RT @RWittenbrink: Und auch diese Studie zeigt den potenziellen therapeutischen Nutzen von niedrig dosiertem Naltrexon bei Myalgischer Enzep…
RT @RWittenbrink: Und auch diese Studie zeigt den potenziellen therapeutischen Nutzen von niedrig dosiertem Naltrexon bei Myalgischer Enzep…
RT @RWittenbrink: Und auch diese Studie zeigt den potenziellen therapeutischen Nutzen von niedrig dosiertem Naltrexon bei Myalgischer Enzep…
Und auch diese Studie zeigt den potenziellen therapeutischen Nutzen von niedrig dosiertem Naltrexon bei Myalgischer Enzephalomyelitis/Chronischem Müdigkeitssyndrom auf: https://t.co/DmG94ivVJN #MECFS #LongCovid #COVID19
@poodlefloop1 To give to you doctor perhaps: Cabanas, H, et al, (2021) Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Immunology, 12(9), 1–12. https://t.co/LxfuL8aCV6
@a_kruschke Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3(TRPM3)Ion Channels https://t.co/mZH8iUxSpO the effect of LDN on TRPM3 ion channel function in NK cells in ME/CFS patients
Also, crohns disease, parkinson's, HIV/AIDS, cancer patients and more. Here's some information: https://t.co/w0c8Da2RKC https://t.co/fkc7ja9616 https://t.co/iZksRhwfUl https://t.co/jNGS4ctgqB ☝️the video mentions using #LDN with #longcovid. It's very good. #covid19
@DataDrivenFP @ahandvanish @polybioRF @microbeminded2 @MBVanElzakker @BhupeshPrusty @ngklimas @nathavindra @DrMaureenHanson @Be_Kinderr Interesting. I wonder if that’s why LDN can be helpful in ME/cfs? It’s an off label treatment. I’m just a curious lay person so that may not be a link, but that’s what popped into my head when you mentioned dopamine receptor. https://t.co/hFTCpCi7us
RT @ResearchFeature: Professor Sonya Marshall-Gradisnik sheds new light on the pathological processes underlying myalgic encephalomyelitis/…
RT @ResearchFeature: Professor Sonya Marshall-Gradisnik sheds new light on the pathological processes underlying myalgic encephalomyelitis/…
RT @ResearchFeature: Professor Sonya Marshall-Gradisnik sheds new light on the pathological processes underlying myalgic encephalomyelitis/…
RT @ResearchFeature: Professor Sonya Marshall-Gradisnik sheds new light on the pathological processes underlying myalgic encephalomyelitis/…
RT @ResearchFeature: Professor Sonya Marshall-Gradisnik sheds new light on the pathological processes underlying myalgic encephalomyelitis/…
Professor Sonya Marshall-Gradisnik sheds new light on the pathological processes underlying myalgic encephalomyelitis/chronic fatigue syndrome (#ME/#CFS). These discoveries now paves the way for future #pharmacotherapeutic interventions. Watch now: https://t.co/CHKYiofZvi
@radicbozo81 Evo i linka: https://t.co/87GIUAcJTH
@driftersmomma @doctorasadkhan @gezmedinger @j_b_kennedy https://t.co/f77LwUYZ8C
@sibylle_berlin Were u looking at quinoline toxicity? I might be wrong but there could be a connection w/ ME. I'm not an expert. Quinolones are antagonists of TRP-V channels. TRP-M channelopathy is being studied as M.E. trigger, don't know if V too https://t.co/ihk3lnqSuP
@sbhank https://t.co/4319b2nB0D
Frontiers | Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment | Immunology https://t.co/4319b2nB0D
Frontiers | Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment | Immunology https://t.co/4319b2nB0D
@doctorsaluja @fitterhappierAJ Neurohormesis It blocks a second channel with a direct effect on TRP channels It's explained for myalgic encephalomyelitis here https://t.co/ihk3lnqSuP
In case someone needs to show evidence of LDN in ME/CFS, this study shows how LDN restores Natural Killer cells' activity in patients with ME/CFS: https://t.co/rQ52S2hL3M
@mrzphd @ahandvanish @resiapretorius @dbkell @doctorasadkhan @MBVanElzakker @microbeminded2 @mrzphd https://t.co/cQDPqoU0cx https://t.co/d7wbr0vuvs https://t.co/hDJIXbP4Jk
RT @RenzPolster: @zweinebelkerzen @sibylle_berlin of what? LDN? These are very low doses compared to what has been suggested for ME/CFS "Ba…
@zweinebelkerzen @sibylle_berlin of what? LDN? These are very low doses compared to what has been suggested for ME/CFS "Based on the benefits reported by patients on their symptoms, low dose NTX (LDN, 3.0–5.0 mg/day) treatment seems to offer some potential benefit..." https://t.co/a2Wqcu6JrL
RT @MelanieWeckert: Frontiers | Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome:…
Frontiers | Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment | Immunology. Will try LDN next https://t.co/s2vh0cyWZI
@pausedME I hope you can find a possibility to try this. It takes at least 5- 10 treatments to notice a significant improvement. I'm also working with a doctor called Hans Schönberger (Bayrisch Zell) who treats a lot of CFS patients with LDN: https://t.co/FEC7qufiVs
@hthsci4bb3 EVIDENCE ➡️ Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. https://t.co/PcbRkBcKmh #4bb3neuroimmune
Potential Therapeutic Benefit of Low Dose Naltrexone in #MECFS: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment https://t.co/lv2jhPwHtn "ME/CFS patients taking LDN have restored TRPM3-like ionic currents in NK cells"
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment https://t.co/oAV8HS4Icy
RT @AmmesAdmin: Research: Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role…
RT @AmmesAdmin: Research: Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role…
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of… https://t.co/UFIYSvOvEf
RT @AmmesAdmin: Research: Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role…
RT @AmmesAdmin: Research: Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role…
RT @AmmesAdmin: Research: Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role…
Research: Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment. https://t.co/eJbRN1BOBy #MECFS
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment https://t.co/w3lkhqbmo6
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment by Helene Cabanas https://t.co/IA3457O2ho
RT @theinvisible81: @maureviv @DrEReinhold @lunettaporchett @KentuckyEntwife https://t.co/SvqUHSXT08 This study recently published, not sur…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
Scientific study on a possible treatment for ME. https://t.co/tS06wWiOjg #ChronicFatigueSyndrome #MyalgicEncephalomyelitis #longhaulers #MEcfs #MyE #CFS #ME #pwME #Forward_ME #millionsmissing #LongCovid
Research: Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment. https://t.co/adE1fua6i3 #MECFS
RT @TomKindlon: "Potential Therapeutic Benefit of #LowDoseNaltrexone in #MyalgicEncephalomyelitis/#ChronicFatigueSyndrome: Role of Transien…
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment https://t.co/wOqAzGZReK
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @TomKindlon: "Potential Therapeutic Benefit of #LowDoseNaltrexone in #MyalgicEncephalomyelitis/#ChronicFatigueSyndrome: Role of Transien…
Why LDN helps many #pwME: Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment https://t.co/ne0pRuhRxn #mecfs #MillionsMissing
RT @BettinafightsME: #MEAwarenessHour "...that LDN treatment results in the enhancement of the analgesic effects & may be relevant in #MECF…
#MEAwarenessHour "...that LDN treatment results in the enhancement of the analgesic effects & may be relevant in #MECFS where insuff.secretion of opioid peptides affects immune-response or pain control...(role of TRPM3 ion channel function in NK cells)." https://t.co/3hZmJXNbjJ https://t.co/do5IxWQSUS
Frontiers | Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment | Immunology https://t.co/0jfzme6ybb
https://t.co/z6l7afoj7J https://t.co/VLdVfVF1eh
RT @VibekeVind: Potential therapeutic benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transie…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
@DrDavidBuckley https://t.co/sIkr7u9L84
@FergalBowers https://t.co/sIkr7u9L84
@GpTrainees https://t.co/sIkr7u9L84
@ICGPnews https://t.co/sIkr7u9L84
@WesselyS https://t.co/sIkr7u9L84
@PaulGarnerWoof https://t.co/sIkr7u9L84
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @TomKindlon: "Potential Therapeutic Benefit of #LowDoseNaltrexone in #MyalgicEncephalomyelitis/#ChronicFatigueSyndrome: Role of Transien…
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment #MECFS #PwME #LDN https://t.co/nAzeyh8vbz
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @VibekeVind: Potential therapeutic benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transie…
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
New Research: Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment: Myalgic… https://t.co/XbBvvedHIi #immunology
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
RT @TomKindlon: "Potential Therapeutic Benefit of #LowDoseNaltrexone in #MyalgicEncephalomyelitis/#ChronicFatigueSyndrome: Role of Transien…
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
"Potential Therapeutic Benefit of #LowDoseNaltrexone in #MyalgicEncephalomyelitis/#ChronicFatigueSyndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment" Free: https://t.co/2KRwXZ5lfp #MEcfs #CFS #MyalgicE
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
RT @neurostingl: Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wie…
Interessante Studie über den möglichen zellulären Effekt von Low Dose Naltrexon bei #MECFS. Klinisch zeigen sich immer wieder erfreuliche Effekte, auch wenn es natürlich das Grundproblem nicht lösen kann. https://t.co/YefjXsjA3o
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @StenHelmfrid: Research paper: In vitro study shows that patients with #MECFS who are taking LDN have restored TRPM3-like ionic currents…
RT @VibekeVind: Potential therapeutic benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transie…
Potential therapeutic benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 ion channels in pathophysiology and treatment. #MEartikler https://t.co/E9fkuCioG2